Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8A | O60658 | 10/20 | 0.56 |
| ▸ | YTHDC1 | Q96MU7 | 5/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236128 | 0.88 | YTHDC1 (0.71) | PDE8AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL822916 | 0.87 | YTHDC1 (0.57) | YTHDC1 | |
| SCHEMBL13596787 | 0.85 | PDE8A (0.62) | PDE8AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL1146681 | 0.83 | YTHDC1 (0.67) | PDE8AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL7204689 | 0.83 | PDE8A (0.60) | PDE8AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL2060472 | 0.82 | PDE4A (0.67) | PDE8AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL21076723 | 0.81 | PDE8A (0.57) | PDE8AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL15306090 | 0.80 | NSD2 (0.46) | YTHDC1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23764385 | 0.80 | PDE8A (0.59) | PDE8AYTHDC1PDE4APDE4BPDE4C | |
| SCHEMBL822730 | 0.79 | TLR7 (0.53) | PDE8AYTHDC1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025040743-A1 | CONJUGATED TLR7 AND RIG-I AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2025-02-27 | — | — | WO | disclosed |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-08-08 | — | — | US | disclosed |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-07-25 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| WO-2024092067-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2023-11-30 | — | — | US | disclosed |
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | UNIVERZA V LJUBLJANI (SI) | 2023-11-30 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| WO-2011134669-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134668-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| CN-101790380-A | The conjugate and the application thereof of synthetic TLR agonist | UNIV CALIFORNIA | 2010-07-28 | — | — | CN | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| CN-101304748-A | Tlr agonists | UNIV CALIFORNIA (US) | 2008-11-12 | — | — | CN | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | CD4, IL4, CCR4 | PDE8A 2008/4885YTHDC1 3866/4885PDE4A 2156/4885 |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | PDE8A 4351/4885YTHDC1 2516/4885PDE4A 4568/4885 |
| US-20090324551-A1 | TLR AGONISTS | TLR3, TLR1, TLR5 | PDE8A 2214/4885YTHDC1 3900/4885PDE4A 1351/4885 |
| US-20230382886-A1 | CONJUGATED TLR7 AND NOD2 AGONISTS | NOD2, TLR7, TLR9 | PDE8A 941/4885YTHDC1 3725/4885PDE4A 914/4885 |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | PDE8A 3659/4885YTHDC1 4323/4885PDE4A 4507/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | PDE8A 3659/4885YTHDC1 4323/4885PDE4A 4507/4885 |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | PDE8A 3659/4885YTHDC1 4323/4885PDE4A 4507/4885 |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | PDE8A 588/4885YTHDC1 4672/4885PDE4A 157/4885 |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | PDE8A 3659/4885YTHDC1 4323/4885PDE4A 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.